Compare GSK plc (GSK) vs Zoom Video Communications, Inc. (ZM) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Zoom Communications (ZM) trades at $91.14, down 0.81% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings, beating estimates with EPS of $1.55, and maintains robust profitability with a net income margin of 41.99%. Recent developments include the acquisition of Common Room and expansion of AI-powered Virtual Agent capabilities, signaling growth initiatives.

The outlook for ZM is cautiously optimistic, supported by solid cash flow, AI integration, and a consensus price target of $118.79 implying significant upside. Key risks include competitive pressure from tech giants and fluctuating cash flow trends, with net cash flow turning negative in 2025. Analyst sentiment is mixed, with 38.78% buy ratings but a majority hold recommendation, reflecting growth potential tempered by execution concerns.